2026 guide: dosing, side effects, timeline & who benefits
HR decision-makers are closely following the surge in demand for the medications, intently considering their plans, and seeking more information from trusted sources to help them reach a decision
Singh highlighted two 2025 studies: one found GLP-1 use was associated with a lower incidence of progression to advanced AMD, including neovascular AMD and geographic atrophy, while another reported an increased risk of neovascular AMD among GLP-1 users
Clinical evidence suggests that whilst these medicines do not directly damage the eyes, they may be associated with worsening diabetic retinopathy in certain patients, particularly those with pre-existing eye disease who experience rapid improvements in blood glucose control
In a review published in Obstetrics & Gynecology, Finkle noted that GLP-1 receptor agonists may exert anti-inflammatory effects on these tissues